Buy CRDL by Oct 18, 2026.

A lot of biotech attention goes to oncology, obesity, and rare disease, but cardiovascular disease is still one of the biggest markets in the sector. Reuters noted cardiovascular disease is one of the areas drawing buyer interest as pharma looks for assets that can offset patent cliffs. That is why I think Cardiol’s positioning is more interesting than the market gives it credit for. It is not trying to be another broad “platform” story with no near-term readout. It is …